2020 Early Career Investigator Presenters

G-CAN 2020 Ralph H. Schumacher Memorial Early Career Investigator Lecture

Wozniak, Jacob, San Diego, US; Robert Terkeltaub, Mentor.
Sustained xanthine oxidase inhibitor treat to target urate lowering therapy (XOIT2T) coordinately re-wires IL-8 and the blood mononuclear leukocyte mitochondrial and inflammation proteome in gout.

Oral Presenters

Genomic regions jointly associated with eGFR and serum urate: Implications for shared genetic etiology of hyperuricemia and chronic kidney disease.

Assessing the causal relationships between insulin resistance and hyperuricemia using bi-directional Mendelian randomization.

3. Meyer, Melissa, La Jolla, US; Catherine Hedrick, Mentor.
Phagocyte Heterogeneity in Resolution of Model Gouty Inflammation.

Sex differences in expression of renal urate transporters.

5. Leask, Megan, Dunedin, New Zealand; Tony Merriman, Mentor.
Translating the multi-trait regulatory landscape at SLC2A9.

The protective impact of physical activity on the risk of gout in women: prospective cohort study of 82,351 women over 30 years.

Poster Presenters

1. Yokose, Chio, Boston, US; Hyon Choi, Mentor.
Effects of low-fat, Mediterranean, or low-carbohydrate weight loss diets on serum urate and cardiometabolic risk factors over 24 Months; A secondary analysis of a randomized trial.

2. Jatuworapruk, Kanon, Wellington, New Zealand; William Taylor, Mentor.
Prediction rule for inpatient gout flare in people with comorbid gout: derivation and external validation.

3. Helget, Lindsay, Omaha, US; Ted Mikuls, Mentor.
Cause-specific mortality in patients with gout in the Veteran’s Health Administration: A matched cohort study.
4. **Cai, Ken**, Auckland, New Zealand; **Nicola Dalbeth, Mentor.** The association between gout and cardiovascular disease outcomes: assessment and recalibration of individual-level primary prevention risk prediction equations in approximately 450,000 New Zealanders.

5. **Vargas-Santos, Ana Beatriz**, Boston, US; **Tuhina Neogi, Mentor.**
   Sodium-glucose co-transporter-2 inhibitors and the risk for gout – A comparison among Canagliflozin, Dapagliflozin and Empagliflozin.

6. **Sumpter, Nick**, Birmingham, US; **Tony Merriman, Mentor.**
   Analysis of common gout comorbidities in the UK Biobank Cohort reveals sex-specific effects and genetic differentiation.

7. **McCormick, Natalie**, Boston, US; **Hyon Choi, Mentor.**
   Prospective study of the patterns of joint involvement for sequential gout flares.

8. **Flood, Rachel**, Tallaght, Ireland; **Ronan Mullan, Mentor.**
   Metatarsophalangeal joint medial collateral ligament measurement: A novel ultrasound feature of monosodium urate deposition in the joint.

9. **Toprover, Michael**, New York, US; **Michael Pillinger, Mentor.**
   Initiating gout treatment improves arterial function and reduces intercritical inflammation.

10. **Murdoch, Rachel**, Auckland, New Zealand; **Nicola Dalbeth, Mentor.**

11. **Roman, Youssef**, Richmond, US; **Elvin Price, Mentor.**
   Genetic perspective on the prevalence of hyperuricemia and gout across major racial groups.

12. **Helget, Lindsay**, Omaha, US; **Ted Mikuls, Mentor.**
    Risk factors for mortality among patients with gout in the Veteran’s Health Administration.

13. **Toprover, Michael**, New York, US; **Michael Pillinger, Mentor.**
    Gout and serum urate levels are associated with lumbar spine monosodium urate deposition and chronic low back pain: A dual-energy CT study.

14. **Calabuig, Irene**, Alicante, Spain; **Mariano Andrés, Mentor.**
    Cardiovascular and renal outcomes during the first year of urate-lowering therapy in naïve-gout according to sonographic joint deposits: data from the Lille-Alicante inception cohort.

15. **Dombrosky Evan**, Richmond, US; **Nehal Shah, Mentor.**
    Assessing patterns of inpatient gout management with focus on urate-lowering therapy and discharge instructions.
16. **Alduraibi, Fatima**, US; **Ahmed Al-Shaikh, Mentor**.
   Role of inflammatory and oxidative stress pathway biomarkers in renal disease in gout.

17. **Gavin, Josh**, Richmond, US; **Nehal Shah, Mentor**
   A survey comparing gout management practice patterns of G-CAN members to other rheumatologists.

18. **Gromova, Margarita**, Moscow, Russia; **Vladimir Tsurko, Mentor**.
   Complex scintigraphic evaluation of renal and urinary tract dysfunction in patients with arterial hypertension and gout.

19. **Kulhawy-Wibe, Stephanie**, Calgary, Canada; **Paul MacMullan, Mentor**.
   Development of a provincial adult inpatient gout management clinical decision-making tool and order set.